Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
4,434
Employees4,434
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
4,434
Employees4,434

NTRA Key Statistics

Market cap
23.55B
Market cap23.55B
Price-Earnings ratio
-88.64
Price-Earnings ratio-88.64
Dividend yield
Dividend yield
Average volume
1.24M
Average volume1.24M
High today
$173.62
High today$173.62
Low today
$167.33
Low today$167.33
Open price
$170.46
Open price$170.46
Volume
1.05M
Volume1.05M
52 Week high
$183.00
52 Week high$183.00
52 Week low
$117.27
52 Week low$117.27

NTRA News

Simply Wall St 2d
Natera's Enrollment Surge in EXPAND Trial Could Be a Game Changer for Natera

Natera recently announced a major milestone in its EXPAND clinical trial, surpassing 1,600 enrolled patients for the Fetal Focus single gene noninvasive prenata...

Natera's Enrollment Surge in EXPAND Trial Could Be a Game Changer for Natera
Simply Wall St 4d
Natera: Exploring Valuation as Share Price Pulls Back Despite Strong Growth

Natera (NTRA) shares have pulled back by roughly 5% over the past month, even after reporting double-digit annual revenue growth and significant improvements in...

Natera: Exploring Valuation as Share Price Pulls Back Despite Strong Growth
Simply Wall St 5d
Natera: Assessing Valuation Potential as Shares Enter a Quiet Phase

Natera (NTRA) shares have seen modest movement during a relatively quiet period. This offers investors a chance to reassess the company’s fundamentals and consi...

Natera: Assessing Valuation Potential as Shares Enter a Quiet Phase

Analyst ratings

90%

of 21 ratings
Buy
90.5%
Hold
4.8%
Sell
4.8%

More NTRA News

TipRanks 7d
Natera enrolls over 1,600 patients in EXPAND trial

Natera (NTRA) announced a milestone in the EXPAND trial with the enrollment of over 1,600 patients. Elevate Your Investing Strategy: Take advantage of TipRank...

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.